Haleon plc (NYSE:HLN) is deemed one of the best NYSE stocks to buy under $20, according to a report by Morgan Stanley on August 4, maintaining a Buy rating with a price target of $10.95.

Haleon plc (NYSE:HLN) reported unaudited results for H1 2025 on June 30, showcasing growth in EMEA & LatAm and Asia-Pacific, while excelling in Oral Health.

Management highlighted organic revenue growth in EMEA & LatAm (+5.2%) and Asia-Pacific (+5.0%), offsetting a 0.4% decline in North America due to a weak US consumer and retail environment.

The company reported that 58% of businesses maintained or gained market share, demonstrating brand portfolio resilience. Free cash flow for H1 reached £734 million, up £184 million year-on-year.

Haleon plc (NYSE:HLN) focuses on consumer healthcare products, operating across North America, EMEA and LatAm, and Asia Pacific.

While acknowledging HLN’s investment potential, some AI stocks offer greater upside with less downside risk. A free report on the best short-term AI stock is available for those seeking an undervalued option benefiting from Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: Morgan Stanley Maintains a Buy on Haleon plc (HLN) With a PT of $10.95